122 related articles for article (PubMed ID: 26011027)
1. Development and analysis of furazolidone-resistant Escherichia coli mutants.
Martínez-Puchol S; Gomes C; Pons MJ; Ruiz-Roldán L; Torrents de la Peña A; Ochoa TJ; Ruiz J
APMIS; 2015 Aug; 123(8):676-81. PubMed ID: 26011027
[TBL] [Abstract][Full Text] [Related]
2. Novel 5-Nitrofuran-Activating Reductase in Escherichia coli.
Le VVH; Davies IG; Moon CD; Wheeler D; Biggs PJ; Rakonjac J
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481448
[TBL] [Abstract][Full Text] [Related]
3. Oxygen-insensitive nitroreductases: analysis of the roles of nfsA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli.
Whiteway J; Koziarz P; Veall J; Sandhu N; Kumar P; Hoecher B; Lambert IB
J Bacteriol; 1998 Nov; 180(21):5529-39. PubMed ID: 9791100
[TBL] [Abstract][Full Text] [Related]
4. Unravelling mechanisms of nitrofurantoin resistance and epidemiological characteristics among Escherichia coli clinical isolates.
Zhang X; Zhang Y; Wang F; Wang C; Chen L; Liu H; Lu H; Wen H; Zhou T
Int J Antimicrob Agents; 2018 Aug; 52(2):226-232. PubMed ID: 29753133
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Genetic Bases of Nitrofurantoin Resistance in Clinical Isolates of Two Successful Multidrug-Resistant Clones of Salmonella enterica Serovar Typhimurium: Pandemic "DT 104" and pUO-StVR2.
García V; Montero I; Bances M; Rodicio R; Rodicio MR
Microb Drug Resist; 2017 Jun; 23(4):405-412. PubMed ID: 27809653
[TBL] [Abstract][Full Text] [Related]
6. Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants.
Pons MJ; Mensa L; Gascón J; Ruiz J
Microb Drug Resist; 2012 Aug; 18(4):376-9. PubMed ID: 21711150
[TBL] [Abstract][Full Text] [Related]
7. In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria.
Le VVH; Olivera C; Spagnuolo J; Davies IG; Rakonjac J
BMC Microbiol; 2020 Jan; 20(1):5. PubMed ID: 31906851
[TBL] [Abstract][Full Text] [Related]
8. Which mechanisms of azithromycin resistance are selected when efflux pumps are inhibited?
Gomes C; Martínez-Puchol S; Durand D; Lluque A; Mosquito S; Ochoa TJ; Ruiz J
Int J Antimicrob Agents; 2013 Oct; 42(4):307-11. PubMed ID: 23871456
[TBL] [Abstract][Full Text] [Related]
9. In vitro development and analysis of Escherichia coli and Shigella boydii azithromycin-resistant mutants.
Gomes C; Pons MJ; Magallon-Tejada A; Durand D; Lluque A; Mosquito S; Riveros M; Mercado E; Prada A; Ochoa TJ; Ruiz J
Microb Drug Resist; 2013 Apr; 19(2):88-93. PubMed ID: 23176550
[TBL] [Abstract][Full Text] [Related]
10. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli.
Sandegren L; Lindqvist A; Kahlmeter G; Andersson DI
J Antimicrob Chemother; 2008 Sep; 62(3):495-503. PubMed ID: 18544599
[TBL] [Abstract][Full Text] [Related]
11. Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF).
Bohnert JA; Schuster S; Fähnrich E; Trittler R; Kern WV
J Antimicrob Chemother; 2007 Jun; 59(6):1216-22. PubMed ID: 17062614
[TBL] [Abstract][Full Text] [Related]
12. CRP regulator modulates multidrug resistance of Escherichia coli by repressing the mdtEF multidrug efflux genes.
Nishino K; Senda Y; Yamaguchi A
J Antibiot (Tokyo); 2008 Mar; 61(3):120-7. PubMed ID: 18503189
[TBL] [Abstract][Full Text] [Related]
13. An in vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli.
Vervoort J; Xavier BB; Stewardson A; Coenen S; Godycki-Cwirko M; Adriaenssens N; Kowalczyk A; Lammens C; Harbarth S; Goossens H; Malhotra-Kumar S
Antimicrob Agents Chemother; 2014 Dec; 58(12):7225-33. PubMed ID: 25246406
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.
Chenia HY; Pillay B; Pillay D
J Antimicrob Chemother; 2006 Dec; 58(6):1274-8. PubMed ID: 17040923
[TBL] [Abstract][Full Text] [Related]
15. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability.
Ruiz J; Mensa L; Pons MJ; Vila J; Gascon J
J Antimicrob Chemother; 2008 May; 61(5):1016-9. PubMed ID: 18325895
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
[TBL] [Abstract][Full Text] [Related]
17. Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome.
Guglierame P; Pasca MR; De Rossi E; Buroni S; Arrigo P; Manina G; Riccardi G
BMC Microbiol; 2006 Jul; 6():66. PubMed ID: 16857052
[TBL] [Abstract][Full Text] [Related]
18. Sixteen homologs of the mex-type multidrug resistance efflux pump in Bacteroides fragilis.
Ueda O; Wexler HM; Hirai K; Shibata Y; Yoshimura F; Fujimura S
Antimicrob Agents Chemother; 2005 Jul; 49(7):2807-15. PubMed ID: 15980353
[TBL] [Abstract][Full Text] [Related]
19. Genetic variations in the active efflux pump genes acrA/B and tolC in different drug-induced strains of Escherichia coli CVCC 1547.
Liu JH; Pan YS; Yuan L; Wu H; Hu GZ; Chen YX
Genet Mol Res; 2013 Aug; 12(3):2829-36. PubMed ID: 24065639
[TBL] [Abstract][Full Text] [Related]
20. [In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate].
Alarcón T; de la Obra P; Domingo D; García-Campos JA; Díaz-Regañón J; López-Brea M
Rev Esp Quimioter; 2005 Dec; 18(4):313-8. PubMed ID: 16446791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
